11月20日的资金流向数据方面，主力资金净流出728.02万元，占总成交额19.7%，游资资金净流入354.0 万元，占总成交额9.58%，散户资金净流入374.02万元，占总成交额10.12%。 近5日资金流向一览见下表： 证券之星消息，截至2025年11月20日收盘，祥生医疗(688358)报收于31.97元，下跌2.65%，换手率 1.02%，成交量1.14万手，成交额3696.15万元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净街入 游资净占比 散户净拓入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-20 | 31.97 -2.65% | | -728.02万 | -19.70% | 354.00万 | 9.58% | 374.02万 | - 10.12% | | 2025-11-19 | 32.84 | -2.73% | र -55.91万 | -2.05% | 431.92万 | 15.81% | -376.01万 | -13.76% | | 20 ...

证券之星消息，截至2025年11月19日收盘，祥生医疗(688358)报收于32.84元，下跌2.73%，换手率 0.74%，成交量8261.0手，成交额2732.13万元。 11月19日的资金流向数据方面，主力资金净流出55.91万元，占总成交额2.05%，游资资金净流入431.92 万元，占总成交额15.81%，散户资金净流出376.01万元，占总成交额13.76%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-19 | 32.84 | -2.73% | -55.91万 | -2.05% | 431.92万 | 15.81% | -376.01万 | -13.76% | | 2025-11-18 | | 33.76 0.72% | 214.01万 | 7.51% | 97.99万 | 3.44% | -312.00万 | -10.95% | | 2025-11-17 | ...

该股主要指标及行业内排名如下： 证券之星消息，截至2025年11月17日收盘，祥生医疗(688358)报收于33.52元，下跌0.89%，换手率 0.9%，成交量1.01万手，成交额3371.48万元。 11月17日的资金流向数据方面，主力资金净流入19.5万元，占总成交额0.58%，游资资金净流入316.37 万元，占总成交额9.38%，散户资金净流出335.87万元，占总成交额9.96%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-17 | 33.52 | -0.89% | 19.50万 | 0.58% | 316.37万 | 9.38% | -335.87万 | -9.96% | | 2025-11-14 | 33.82 | 1.84% | -4.70万 | -0.09% | -408.15万 | -7.49% | 412.85万 | 7.58% | | 2025-1 ...

证券之星消息，截至2025年11月14日收盘，祥生医疗(688358)报收于33.82元，上涨1.84%，换手率 1.43%，成交量1.6万手，成交额5446.46万元。 11月14日的资金流向数据方面，主力资金净流出4.7万元，占总成交额0.09%，游资资金净流出408.15万 元，占总成交额7.49%，散户资金净流入412.85万元，占总成交额7.58%。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-14 | 33.82 1.84% | -4.70万 | -0.09% | -408.15万 | -7.49% | 412.85万 | 7.58% | | 2025-11-13 | 33.21 0.76% | -199.35万 | -4.27% | -152.80万 | -3.27% | 352.15万 | 7.54% | | 2025-11-12 | 32.96 -2.66% | -1016.31万 | -14.71% ...

11月12日，祥生医疗盘中下跌2.01%，截至11:20，报33.18元/股，成交3441.28万元，换手率0.91%，总 市值37.20亿元。 资金流向方面，主力资金净流出268.70万元，大单买入500.71万元，占比14.55%，卖出769.41万元，占 比22.36%。 祥生医疗今年以来股价涨41.66%，近5个交易日跌5.47%，近20日跌0.06%，近60日跌4.38%。 责任编辑：小浪快报 祥生医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：QFII持股、小盘、高派 息、融资融券、出海概念等。 截至9月30日，祥生医疗股东户数6167.00，较上期减少7.00%；人均流通股18181股，较上期增加 7.52%。2025年1月-9月，祥生医疗实现营业收入3.43亿元，同比减少5.27%；归母净利润9392.05万元， 同比减少4.56%。 分红方面，祥生医疗A股上市后累计派现4.64亿元。近三年，累计派现2.80亿元。 机构持仓方面，截止2025年9月30日，祥生医疗十大流通股东中，长城消费增值混合A（200006）、华 安宏利混合A（040005）退出十大流通股东之列。 今年 ...

Summary of Key Points Core Viewpoint - On November 7, 2025, Xiangsheng Medical (688358) closed at 34.92 yuan, experiencing a decline of 0.6% with a trading volume of 19,900 shares and a total transaction value of 69.129 million yuan [1]. Trading Information - On November 7, the net inflow of main funds was 3.7046 million yuan, accounting for 5.36% of the total transaction value [2]. - Retail investors had a net outflow of 4.9732 million yuan, representing 7.19% of the total transaction value [1]. Company Announcements - From September 5 to November 6, 2025, shareholder Mo Ruoli reduced his holdings by 1,783,139 shares, which is 1.59% of the total share capital [1][2]. - Following this reduction, Mo Ruoli and his concerted parties' total shareholding decreased from 71.99% to 70.40%, triggering the 1% equity change disclosure standard [1].

Core Insights - The company, Wuxi Xiangsheng Medical Technology Co., Ltd., is leveraging its deep technical expertise in ultrasound and innovation capabilities to navigate challenges, showing a stable upward trend in operational performance [1] - Xiangsheng Medical is actively embracing the "AI + Ultrasound" technology trend and is advancing its animal ultrasound business, aiming to deepen collaboration with global partners [1] Group 1: AI Ultrasound Innovations - As a leader in the AI ultrasound field, the company is establishing a comprehensive intelligent technology ecosystem driven by "ultrasound artificial intelligence + specialized models" [1] - The company has developed an intelligent standard framework covering "equipment research and development - image acquisition - diagnostic decision-making," creating a service network that integrates "precise screening - intelligent diagnosis - personalized rehabilitation" [1] Group 2: Veterinary Ultrasound Products - In 2025, the company successfully launched the SonoVet series of veterinary ultrasound products, which cater to various applications such as large animal reproduction and small animal abdominal and cardiovascular examinations [1] - These products are designed to meet diverse environmental needs in settings like farms, pet hospitals, mobile quarantine, and wildlife care, addressing pain points such as low image resolution and reliance on operator experience in traditional veterinary ultrasound [1] Group 3: Robotics and AI Integration - In addition to AI technology integration, the company has made significant breakthroughs in the robotics field, developing core technologies such as "visual recognition and analysis" and "precise control of robotic movement" [2] - The company has launched the "AI + Robot Scanning" series of solutions, with its flagship product, the "Breast Artificial Intelligence Ultrasound Robot," being the first to obtain a medical device testing report [2]

Core Viewpoint - The announcement details a significant equity change involving major shareholders of Wuxi Xiangsheng Medical Technology Co., Ltd., specifically regarding the reduction of shareholding by over 1% [3][4]. Group 1: Shareholder Information - The main shareholder, Mo Ruoli, along with her concerted parties, including Wuxi Xiangsheng Investment Co., Ltd., Wuxi Xiangding Investment Enterprise (Limited Partnership), Wuxi Xiangtong Investment Enterprise (Limited Partnership), and Shanghai Yude Technology Co., Ltd., is responsible for the disclosed information [2][3]. - The actual controllers of the company, Mo Shanjuo, Mo Ruoli, and Lu Jian, are identified as concerted actors [2]. Group 2: Equity Change Details - Mo Ruoli reduced her shareholding by 1,783,139 shares, representing 1.59% of the total share capital, between September 5, 2025, and November 6, 2025 [3]. - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80,723,956 shares to 78,940,817 shares, with the ownership percentage dropping from 71.99% to 70.40% [3]. Group 3: Additional Notes - This equity change is part of a previously disclosed share reduction plan by Mo Ruoli, as announced on August 15, 2025 [4]. - The reduction was executed through centralized bidding and block trading, and it does not trigger a mandatory tender offer [4]. - The equity change will not alter the controlling shareholder or actual controller of the company, nor will it significantly impact the company's governance structure or ongoing operations [5].

Core Points - The stock of Xiangsheng Medical (688358) closed at 34.92 yuan on November 7, 2025, down 0.6% from the previous trading day, with a total market capitalization of 3.915 billion yuan [1] - The stock opened at 35.1 yuan, reached a high of 35.22 yuan, and a low of 34.26 yuan, with a trading volume of 69.129 million yuan and a turnover rate of 1.78% [1] - The company announced that shareholder Mo Ruoli reduced his stake by 1,783,139 shares, accounting for 1.59% of the total share capital, between September 5 and November 6, 2025 [1] - Following this reduction, Mo Ruoli and his concerted parties' combined shareholding decreased from 71.99% to 70.40%, reaching a 1% integer threshold [1] - This change did not result in a change of the company's controlling shareholder or actual controller, did not trigger a mandatory bid, and did not violate previous commitments [1] Announcement Summary - The announcement regarding the change in equity of shareholders holding more than 5% was made by Xiangsheng Medical [2]

Group 1 - The core point of the article is that Xiangsheng Medical announced a significant reduction in shareholding by a major shareholder, Mo Ruoli, which has implications for the company's ownership structure and potential market perception [1] Group 2 - Mo Ruoli reduced her shareholding by 1,783,139 shares, representing 1.59% of the total share capital of Xiangsheng Medical [1] - Following this reduction, the total shares held by Mo Ruoli and her concerted parties decreased from 80,723,956 shares to 78,940,817 shares, resulting in a change in ownership percentage from 71.99% to 70.40% [1] - This change in equity ownership has triggered a notification as it touches the 1% threshold for reporting [1]